Literature DB >> 30370079

Renal denervation with ultrasound therapy (paradise device) is an effective therapy for systemic hypertension.

Sho Torii1, Hiroyoshi Mori1, Hiroyuki Jinnouchi1, Atsushi Sakamoto1, Aloke Finn1, Renu Virmani1.   

Abstract

Entities:  

Year:  2018        PMID： 30370079      PMCID： PMC6186633          DOI： 10.21037/jtd.2018.08.134

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

2.  Anatomic assessment of sympathetic peri-arterial renal nerves in man.

Authors:  Kenichi Sakakura; Elena Ladich; Qi Cheng; Fumiyuki Otsuka; Kazuyuki Yahagi; David R Fowler; Frank D Kolodgie; Renu Virmani; Michael Joner
Journal:  J Am Coll Cardiol       Date:  2014-08-19       Impact factor: 24.094

3.  Controlled circumferential renal sympathetic denervation with preservation of the renal arterial wall using intraluminal ultrasound: a next-generation approach for treating sympathetic overactivity.

Authors:  Kenichi Sakakura; Austin Roth; Elena Ladich; Kai Shen; Leslie Coleman; Michael Joner; Renu Virmani
Journal:  EuroIntervention       Date:  2015-02       Impact factor: 6.534

4.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

Authors:  Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2012-11-09       Impact factor: 29.983

Review 5.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Authors:  Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi
Journal:  Lancet       Date:  2015-12-24       Impact factor: 79.321

6.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

7.  Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

Authors:  Henry Krum; Markus P Schlaich; Paul A Sobotka; Michael Böhm; Felix Mahfoud; Krishna Rocha-Singh; Richard Katholi; Murray D Esler
Journal:  Lancet       Date:  2013-11-07       Impact factor: 79.321

8.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

9.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

10.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.